Active Solicitation · DEPARTMENT OF HEALTH AND HUMAN SERVICES

    Bundibugyo Virus Outbreak Response Vaccines (BundiVx) - RRPV Consortium

    Sol. RRPV-26-13-BundiVxSolicitationSet-aside: No Set aside usedWASHINGTON, DC
    Open · 9d remaining
    DAYS TO CLOSE
    9
    closes Jul 2, 2026
    POSTED
    Jun 18, 2026
    Publication date
    NAICS CODE
    541714
    Primary industry classification
    PSC CODE
    AN23
    Product & service classification

    AI Summary

    The Department of Health and Human Services seeks proposals for the Bundibugyo Virus Outbreak Response Vaccines project. This includes developing investigational vaccines, manufacturing clinical trial materials, and conducting Phase 1 trials. Proposals are due by June 26, 2026, with questions accepted until June 16, 2026. Interested parties should refer to the provided link for further details.

    Contract details

    Solicitation No.
    RRPV-26-13-BundiVx
    Notice Type
    Solicitation
    Set-Aside
    No Set aside used
    Posted Date
    June 18, 2026
    Response Deadline
    July 2, 2026
    NAICS Code
    541714AI guide
    PSC / Class Code
    AN23
    Contract Code
    7505
    Primary Contact
    Veronica Stroud
    State
    DC
    ZIP Code
    20515
    AI Product/Service
    both

    Description

    UPDATE: Question and Answers attached in documents. Date for submission revised to July 2, 2026. The Office of Biomedical Advanced Research and Development Authority (BARDA), within the Administration for Strategic Preparedness and Response (ASPR) at the U.S. Department of Health and Human Services (HHS) seeks to use the Rapid Response Partnership Vehicle (RRPV) Consortium, an enterprise partnership in collaboration with industry and academia to facilitate research and development activities as follows: The purpose of this RPP is to advance investigational BDBV vaccine candidates leveraging the VSV vaccine platform, which has demonstrated single dose protection in past EBOV outbreaks. Work includes manufacturing process development through production of initial current Good Manufacturing Practice (cGMP) Phase 1 clinical trial material (CTM), with a goal of up to 10,000 doses. Early regulatory engagement will inform the critical-path IND-enabling nonclinical. The proposed approach must describe how any available platform efficiencies from prior or ongoing platform development and manufacturing to accelerate the path towards cGMP CTM production and IND submission under the U.S. FDA. Additional activities include a Phase 1 safety and immunogenicity trial as well as options for production of up to 100,000 doses of cGMP CTM. The end goal of this effort is (1) to produce cGMP CTM and meet regulatory requirements to enable use of investigational candidate(s) in a clinical trial for the ongoing 2026 BDBV outbreak and (2) to identify successful BDBV vaccine candidates for potential further development. Please see the attachments for more information. Questions are due June 16, 2026 by 12 p.m. Eastern. Proposals are due by June 26 at 3 p.m. Eastern. Submission link: https://www.rrpv.org/solicitation/bundibugyo-virus-outbreak-response-vaccines-bundivx/

    Key dates

    1. June 18, 2026Posted Date
    2. July 2, 2026Proposals / Responses Due

    AI search tags

    Frequently asked questions

    Bundibugyo Virus Outbreak Response Vaccines (BundiVx) - RRPV Consortium is a federal acquisition solicitation issued by DEPARTMENT OF HEALTH AND HUMAN SERVICES. Review the full description, attachments, and submission requirements on SamSearch before the response deadline.

    SamSearch Platform

    Stop searching. Start winning.

    AI-powered intelligence for the right opportunities, the right leads, and the right time.